Recent Understanding and Future Directions in the Application of MMP-2 in Encapsulating Peritoneal Sclerosis Clinical Practice

Encapsulating peritoneal sclerosis (EPS) is an uncommon and harmful complication which may cause destructive outcomes. Matrix metalloproteinase-2 (MMP-2) as a protease can reduce constituents of the extracellular matrix and play a crucial role in the progression of EPS. As a new biomarker, MMP-2 may improve the detection rate of EPS patients in clinical work. In this review, we summarize the recent study of MMP-2 in different etiologies and the assessment of its application value and draw attention to its future directions.

Automated summary

Encapsulating peritoneal sclerosis (EPS) is a rare and harmful complication that can lead to destructive outcomes. Matrix metalloproteinase-2 (MMP-2), as a protease, plays a crucial role in the progression of EPS by reducing constituents of the extracellular matrix. As a new biomarker, MMP-2 may enhance the detection rate of EPS patients in clinical practice. This review summarizes the recent studies on MMP-2 in different etiologies, assesses its application value, and highlights future directions.